While targeting the Gas6/Axl pathway has shown promising preclinical and clinical efficacy, targeting Gas6 or Axl as a monotherapy raises a concern about a possible narrow therapeutic index due to its expression and regulation of tumor growth in various cell types of the tumor. Here, AXL is linked to neoplasm.